We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

74 hedge funds and large institutions have $190M invested in Inozyme Pharma in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

313% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 8

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

51% more funds holding

Funds holding: 49 → 74 (+25)

4.4% more ownership

Funds ownership: 73.16% → 77.56% (+4.4%)

4% more capital invested

Capital invested by funds: $183M → $190M (+$6.85M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

52% less call options, than puts

Call options by funds: $126K | Put options by funds: $263K

Holders
74
Holders Change
+25
Holders Change %
+51.02%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
33
Increased
25
Reduced
12
Closed
8
Calls
$126K
Puts
$263K
Net Calls
-$137K
Net Calls Change
+$75K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$8.8M
2
Millennium Management
Millennium Management
New York
+$3.04M
3
State Street
State Street
Massachusetts
+$2.74M
4
PBPIA
Pivotal bioVenture Partners Investment Advisor
California
+$2.65M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.22M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$9.49M
2
SFM
Sphera Funds Management
Israel
-$3.84M
3
Citadel Advisors
Citadel Advisors
Florida
-$3.83M
4
SB
Samsara BioCapital
California
-$2.89M
5
CA
CHI Advisors
New York
-$870K
Name Holding Trade Value Shares
Change 		Change in
Stake
PHP
26
Parkman Healthcare Partners
Connecticut
$940K +$259K +43,790 +35%
UOC
27
UBS O'Connor
Illinois
$865K +$45.2K +7,651 +5%
Citadel Advisors
28
Citadel Advisors
Florida
$811K -$3.83M -648,223 -82%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$789K +$559K +94,539 +200%
N
30
Nuveen
North Carolina
$767K +$814K +137,749 New
Marshall Wace
31
Marshall Wace
United Kingdom
$712K -$397K -67,190 -34%
BCM
32
Bridgeway Capital Management
Texas
$649K -$4.73K -800 -0.7%
Charles Schwab
33
Charles Schwab
California
$492K +$424K +71,708 +433%
Two Sigma Investments
34
Two Sigma Investments
New York
$477K +$119K +20,087 +31%
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$463K +$193K +32,619 +64%
SSA
36
Schonfeld Strategic Advisors
New York
$389K +$244K +41,200 +144%
Acadian Asset Management
37
Acadian Asset Management
Massachusetts
$319K +$340K +57,468 New
Bank of America
38
Bank of America
North Carolina
$309K +$260K +43,955 +381%
Mirae Asset Global Investments
39
Mirae Asset Global Investments
South Korea
$309K +$327K +55,403 New
OCA
40
Octagon Capital Advisors
New York
$277K +$294K +49,702 New
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$242K +$257K +43,411 New
Goldman Sachs
42
Goldman Sachs
New York
$192K +$203K +34,389 New
Morgan Stanley
43
Morgan Stanley
New York
$187K +$84.1K +14,229 +74%
TCWM
44
Total Clarity Wealth Management
Illinois
$169K +$179K +30,300 New
BC
45
BIT Capital
Germany
$162K -$148K -25,097 -46%
GCP
46
GSA Capital Partners
United Kingdom
$149K +$158K +26,804 New
DA
47
Denali Advisors
California
$149K +$158K +26,700 New
JP Morgan Chase
48
JP Morgan Chase
New York
$147K +$155K +26,245 +43,742%
JF
49
Jump Financial
Illinois
$127K +$135K +22,800 New
ECM
50
ExodusPoint Capital Management
New York
$123K +$131K +22,081 New
1
2
3 4

INZY Hedge Fund Activity: Q2 2023 in Review

74 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q2 2023, worth a combined $190M — up 3.7% from $183M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new INZY positions and 8 closed out — a net gain of 25 holders — while 25 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $8.8M. The largest seller was Deep Track Capital, cutting an estimated $9.49M.

  • 74 institutional investors held Inozyme Pharma (INZY) as of Q2 2023, up from 49 in Q1 2023.
  • Funds reported $190M of Inozyme Pharma stock for Q2 2023, up 3.7% quarter-over-quarter.
  • 33 funds opened new Inozyme Pharma positions in Q2 2023 and 8 closed out, a net change of +25 holders.
  • The largest Inozyme Pharma buyer in Q2 2023 was BlackRock, an estimated $8.8M added.
  • The largest Inozyme Pharma seller in Q2 2023 was Deep Track Capital, an estimated $9.49M sold.

Based on aggregated 13F filings for Q2 2023.